| Description | SPI-112, the SPI-112 methyl ester analog, can inhibit cellular Shp2 PTP activity. SPI-112 bound to Shp2 by surface plasmon resonance (SPR) and displayed competitive inhibitor kinetics to Shp2. |
| Target activity | SHP2:1 μM (IC50), PTP1B:14.5 μM (IC50), PTP:18.3 μM (IC50) |
| molecular weight | 468.46 |
| Molecular formula | C22H17FN4O5S |
| CAS | 1051387-90-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (106.73 mM) |
| References | 1. Chen L, et al. Biochem Pharmacol. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112 . 2010 Sep 15;80(6):801-10 2. Wu R, Wang C, Li Z, et al. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA[J]. Journal for immunotherapy of cancer. 2020, 8(2). |
| Citations | 1. Wu R, Wang C, Li Z, et al. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Journal for immunotherapy of cancer. 2020 Nov;8(2):e001037. 2. Lu X, Yu R, Li Z, et al.JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.Cancer Letters.2023: 216517. |